Cargando…

Prognostic and predictive value of human equilibrative nucleoside transporter 1 (hENT1) in extrahepatic cholangiocarcinoma: a translational study

Introduction: Effective (neo) adjuvant chemotherapy for cholangiocarcinoma is lacking due to chemoresistance and the absence of predictive biomarkers. Human equilibrative nucleoside transporter 1 (hENT1) has been described as a potential prognostic and predictive biomarker. In this study, the potent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boyd, Lenka N. C., Nooijen, Lynn E., Ali, Mahsoem, Puik, Jisce R., Moustaquim, Jasmine, Fraga Rodrigues, Stephanie M., Broos, Robert, Belkouz, Ali, Meijer, Laura L., Le Large, Tessa Y. S., Erdmann, Joris I., Hooijer, Gerrit K. J., Heger, Michal, Van Laarhoven, Hanneke W. M., Roos, Eva, Kazemier, Geert, Giovannetti, Elisa, Verheij, Joanne, Klümpen, Heinz-Josef
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619907/ https://www.ncbi.nlm.nih.gov/pubmed/37920204 http://dx.doi.org/10.3389/fphar.2023.1274692

Ejemplares similares

hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients
por: Meijer, Laura L., et al.
Publicado: (2016)

Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions
por: Spratlin, Jennifer L., et al.
Publicado: (2010)

The Diagnostic Value of the CA19-9 and Bilirubin Ratio in Patients with Pancreatic Cancer, Distal Bile Duct Cancer and Benign Periampullary Diseases, a Novel Approach
por: Boyd, Lenka N. C., et al.
Publicado: (2022)

hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status
por: Raffenne, Jerome, et al.
Publicado: (2019)

Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer
por: Kim, Jaihwan, et al.
Publicado: (2018)

Bidirectional transport of 2-chloroadenosine by equilibrative nucleoside transporter 4 (hENT4): Evidence for allosteric kinetics at acidic pH
por: Tandio, David, et al.
Publicado: (2019)

Gestational Diabetes—Placental Expression of Human Equilibrative Nucleoside Transporter 1 (hENT1): Is Delayed Villous Maturation an Adaptive Pattern?
por: Giacometti, Cinzia, et al.
Publicado: (2023)

Novel Strategies to Address Critical Challenges in Pancreatic Cancer
por: Puik, Jisce R., et al.
Publicado: (2022)

Prediction Model for Early-Stage Pancreatic Cancer Using Routinely Measured Blood Biomarkers
por: Boyd, Lenka N. C., et al.
Publicado: (2023)

Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer
por: Elander, N. O., et al.
Publicado: (2018)

Human equilibrative nucleoside transporter-1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression; do they have survival impact to pancreatic cancer?
por: Hwang, Dae Wook, et al.
Publicado: (2020)

ET-7 Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

Unravelling the Diagnostic Dilemma: A MicroRNA Panel of Circulating MiR-16 and MiR-877 as A Diagnostic Classifier for Distal Bile Duct Tumors
por: Meijer, Laura L., et al.
Publicado: (2019)

A predictive analysis of the SP120 and 10D7G2 antibodies for human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine
por: Kalloger, Steve E, et al.
Publicado: (2017)

Diagnostic accuracy and added value of blood-based protein biomarkers for pancreatic cancer: A meta-analysis of aggregate and individual participant data
por: Boyd, Lenka N.C., et al.
Publicado: (2022)

Decreased erythrocyte nucleoside transport and hENT1 transporter expression in glucose 6-phosphate dehydrogenase deficiency
por: Al-Ansari, Mohammad, et al.
Publicado: (2015)

hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA
por: Aughton, Karen, et al.
Publicado: (2021)

hENT1’s role in adjuvant intra-arterial gemcitabine-based chemotherapy for resectable pancreatic cancer patients
por: Wang, Wei, et al.
Publicado: (2023)

Targeting the equilibrative nucleoside transporter ENT1 in Huntington disease
por: Guitart, Xavier, et al.
Publicado: (2017)

Combination treatment with hENT1 and miR-143 reverses gemcitabine resistance in triple-negative breast cancer
por: Xi, Yue, et al.
Publicado: (2022)

Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression
por: Guo, Zhongyi, et al.
Publicado: (2018)

HIF-1–dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia
por: Eltzschig, Holger K., et al.
Publicado: (2005)

Gene expression of hENT1, dCK, CDA, dCMPD and topoisomerase IIα as an indicator of chemotherapy response in AML treated with cytarabine and daunorubicin
por: Kulsoom, Bibi, et al.
Publicado: (2018)

Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer
por: Elebro, Jacob, et al.
Publicado: (2016)

SKM-1细胞地西他滨耐药机制中hENT1功能的研究
Publicado: (2015)

Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice
por: Anderson, Jason T., et al.
Publicado: (2019)

Functional Characterization of the Saccharomyces cerevisiae Equilibrative Nucleoside Transporter 1 (ScENT1)
por: Boswell-Casteel, Rebba C., et al.
Publicado: (2018)

Equilibrative nucleoside transporter 1 (ENT1) is critical for pollen germination and vegetative growth in Arabidopsis
por: Bernard, Carsten, et al.
Publicado: (2011)

Changes in aortic reactivity associated with the loss of equilibrative nucleoside transporter 1 (ENT1) in mice
por: Best, K. Arielle, et al.
Publicado: (2018)

Differential Inhibition of Equilibrative Nucleoside Transporter 1 (ENT1) Activity by Tyrosine Kinase Inhibitors
por: Jouan, Elodie, et al.
Publicado: (2021)

Targeting the Plasmodium vivax equilibrative nucleoside transporter 1 (PvENT1) for antimalarial drug development
por: Deniskin, Roman, et al.
Publicado: (2015)

N-linked glycosylation of N48 is required for equilibrative nucleoside transporter 1 (ENT1) function
por: Bicket, Alex, et al.
Publicado: (2016)

Multidrug‐resistant transporter expression does not always result in drug resistance
por: Le Large, Tessa Ya Sung, et al.
Publicado: (2018)

Targeting myocardial equilibrative nucleoside transporter ENT1 provides cardioprotection by enhancing myeloid Adora2b signaling
por: Ruan, Wei, et al.
Publicado: (2023)

Factors that influence the pancreatic and duodenal microbiome in patients undergoing pancreatic surgery
por: Zwart, Eline S., et al.
Publicado: (2022)

Regulation of hepatic glucose production and AMPK by AICAR but not by metformin depends on drug uptake through the equilibrative nucleoside transporter 1 (ENT1)
por: Logie, Lisa, et al.
Publicado: (2018)

The Association of FLT3-ITD Gene Mutation with Bone Marrow Blast Cell Count, CD34, Cyclin D1, Bcl-xL and hENT1 Expression in Acute Myeloid Leukemia Patients
por: Notopuro, Paulus Budiono, et al.
Publicado: (2020)

Electronegativity Equilibration
por: Sessa, Francesco, et al.
Publicado: (2022)

Decreased Equilibrative Nucleoside Transporter 1 (ENT1) Activity Contributes to the High Extracellular Adenosine Levels in Mesenchymal Glioblastoma Stem-Like Cells
por: Alarcón, Sebastián, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_52sngnei58i5viuc3unjo0va2l